These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 11382726)
21. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Hobbach HP; Schuster P Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467 [TBL] [Abstract][Full Text] [Related]
22. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Madan M; Berkowitz SD; Christie DJ; Smit AC; Sigmon KN; Tcheng JE Am Heart J; 2002 Jul; 144(1):151-8. PubMed ID: 12094202 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention. Cheng JW Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710 [TBL] [Abstract][Full Text] [Related]
24. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. McCollam PL; Foster DA; Riesmeyer JS Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921 [TBL] [Abstract][Full Text] [Related]
25. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843 [TBL] [Abstract][Full Text] [Related]
26. Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI. Puri A; Bansal A; Narain VS; Sethi R; Dwivedi SK; Puri VK; Saran RK Indian Heart J; 2013; 65(2):152-7. PubMed ID: 23647894 [TBL] [Abstract][Full Text] [Related]
27. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. PRICE Investigators Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437 [TBL] [Abstract][Full Text] [Related]
28. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Lincoff AM Am J Cardiol; 1998 Oct; 82(8B):36P-42P. PubMed ID: 9809890 [TBL] [Abstract][Full Text] [Related]
29. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Stone GW; Moliterno DJ; Bertrand M; Neumann FJ; Herrmann HC; Powers ER; Grines CL; Moses JW; Cohen DJ; Cohen EA; Cohen M; Wolski K; DiBattiste PM; Topol EJ Circulation; 2002 May; 105(20):2347-54. PubMed ID: 12021219 [TBL] [Abstract][Full Text] [Related]
30. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria. Kini AS; Reich D; Mitre CA; Sharma SK Am J Cardiol; 2001 Dec; 88(11):1287-90. PubMed ID: 11728356 [No Abstract] [Full Text] [Related]
31. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Simon DI; Liu CB; Ganz P; Kirshenbaum JM; Piana RN; Rogers C; Selwyn AP; Popma JJ Catheter Cardiovasc Interv; 2001 Apr; 52(4):425-32. PubMed ID: 11285593 [TBL] [Abstract][Full Text] [Related]
33. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. Danzi GB; Capuano C; Sesana M; Mauri L; Sozzi FB Am J Cardiol; 2006 Feb; 97(4):489-93. PubMed ID: 16461043 [TBL] [Abstract][Full Text] [Related]
34. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization. Ibbotson T; McGavin JK; Goa KL Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074 [TBL] [Abstract][Full Text] [Related]
35. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. Neumann FJ; Hochholzer W; Pogatsa-Murray G; Schömig A; Gawaz M J Am Coll Cardiol; 2001 Apr; 37(5):1323-8. PubMed ID: 11300442 [TBL] [Abstract][Full Text] [Related]
36. Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy. Juran NB Am Heart J; 1999 Oct; 138(4 Pt 2):297-306. PubMed ID: 10502235 [TBL] [Abstract][Full Text] [Related]
38. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. Ross MJ; Herrmann HC; Moliterno DJ; Blankenship JC; Demopoulos L; DiBattiste PM; Ellis SG; Ghazzal Z; Martin JL; White J; Topol EJ J Am Coll Cardiol; 2003 Sep; 42(6):981-8. PubMed ID: 13678916 [TBL] [Abstract][Full Text] [Related]
39. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Moliterno DJ; Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351 [TBL] [Abstract][Full Text] [Related]
40. IIb's are not IIb's. Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]